Semaglutide and Tirzepatide Titration Schedules: When to Step Up

If you are on a GLP-1 or about to start one, the question that comes up fastest is a practical one: what dose do I take, and when do I move up? The labels answer this precisely. Both semaglutide and tirzepatide use a stepwise escalation schedule — a low starting dose, a fixed holding period, then a defined increase — repeated until you reach a maintenance dose. This piece lays out both schedules in full so you can see exactly where each step lands and what triggers the next one.

Want to see how your own ramp maps onto real calendar dates? You can plug in your start date and map your own schedule to the calendar with our GLP-1 Titration Schedule calculator.

Why the starting dose is deliberately low

The first thing to understand is that the opening dose of any GLP-1 is not a treatment dose. Semaglutide starts at 0.25 mg and tirzepatide at 2.5 mg, and both are chosen for one reason: tolerability. They exist to let your gut begin adapting to the drug, not to drive appetite suppression or weight loss on their own.

The most common side effects — nausea, reduced appetite, constipation, sometimes vomiting or diarrhea — are dose-related and tend to be worst right after a change in dose. Starting low and climbing slowly gives the body time to catch up to each new level before the next increase. This is the whole logic behind the schedule, and it is worth understanding in depth; we cover the reasoning in detail in our companion piece on why slow titration wins.

Semaglutide titration schedule (Wegovy)

Wegovy (semaglutide 2.4 mg) escalates the once-weekly injection through five fixed four-week steps. The schedule below is the standard escalation from the official label:

Weeks	Weekly dose
1–4	0.25 mg
5–8	0.5 mg
9–12	1.0 mg
13–16	1.7 mg
17+	2.4 mg (maintenance)

So it takes roughly 16 weeks of stepwise increases to reach the full 2.4 mg maintenance dose. Each step is held for four weeks before the next increase. The 0.25 mg and 0.5 mg doses in particular are ramp-up doses — they get your gut ready rather than delivering the drug’s full effect.

The label is explicit about what to do when a step is rough: if you don’t tolerate an escalation dose, the next increase can be delayed by four weeks. In other words, the schedule has a built-in pause button. (Note that Ozempic, the type-2-diabetes version of semaglutide, uses a different, lower-dose schedule; the table above is the weight-management Wegovy version.)

Tirzepatide dose schedule (Zepbound / Mounjaro)

Tirzepatide follows the same philosophy but with more optional steps, because its maintenance range is wider. It also starts low and climbs in 2.5 mg increments, once weekly:

Weeks	Weekly dose
1–4	2.5 mg
5–8	5 mg
9–12	7.5 mg (if needed)
13–16	10 mg (if needed)
17–20	12.5 mg (if needed)
21+	15 mg (maximum)

Here the 2.5 mg starting dose is, again, purely for tolerability. At week 5 you move to 5 mg, which is the first maintenance-eligible dose. From there, the label allows an increase of 2.5 mg after at least four weeks on the current dose, as needed to reach the treatment target. The available maintenance doses are 5 mg, 10 mg, and 15 mg, with 7.5 mg and 12.5 mg serving as intermediate steps on the way up.

The phrase “if needed” is doing real work in that table. Unlike Wegovy, where nearly everyone is aiming for the single 2.4 mg maintenance dose, tirzepatide is designed so that many people stop climbing before the maximum. If 5 mg or 10 mg is getting the job done with acceptable side effects, there is no requirement to keep going.

When to increase your GLP-1 dose

Across both drugs, the rule for stepping up is the same, and it comes down to two conditions being met at once:

You have held the current dose for at least four weeks. This is the minimum adaptation window built into both labels. Moving faster than this is not on-label and tends to backfire on tolerability.
You are tolerating the current dose reasonably well. If side effects are still significant, the labels’ own guidance is to delay the increase — commonly by another four weeks at the same dose — rather than push ahead on schedule.

Put simply: the calendar tells you the earliest you can move up; how you feel tells you whether you should. Both have to line up. A step increase is a decision made with your prescriber, not an automatic event that happens because a certain number of weeks have passed.

The maintenance dose is a range, not a finish line

It is easy to read these tables as a race to the top number. They aren’t. The maximum dose is a ceiling, not a goal. The right maintenance dose is the lowest one that achieves your goal with side effects you can live with — and for many people that is not the maximum.

This matters most with tirzepatide, where 5 mg, 10 mg, and 15 mg are all legitimate maintenance doses. Someone doing well on 10 mg has no built-in reason to push to 15 mg. With semaglutide the target maintenance dose is 2.4 mg, but even there, some people settle at a lower dose if it works well enough and higher doses bring more side effects than benefit — a conversation worth having with a prescriber rather than defaulting to the top of the ladder.

Slowing or pausing the ramp is normal

Titration schedules are templates, not commandments. Some people move through every step on time; others need to sit on a dose for an extra cycle, or step back down temporarily when a new dose hits hard. Both labels explicitly accommodate this by allowing delayed increases. Slowing the ramp is a normal, expected adjustment — not a sign of failure or a reason to worry.

A few honest framings that apply to both drugs:

GI side effects are usually most intense in the first weeks and right after each increase, then ease as the body adapts.
Simple habits — smaller meals, eating slowly, staying hydrated, easing off very large or fatty meals — often blunt the worst of it.
Persistent severe symptoms, or anything beyond ordinary GI upset, are a reason to call a clinician rather than tough it out.

The takeaway

The semaglutide and tirzepatide schedules are among the most well-defined parts of using these medications. Semaglutide climbs through five fixed four-week steps to 2.4 mg; tirzepatide starts at 2.5 mg, reaches its first maintenance dose at 5 mg, and can rise by 2.5 mg every four weeks up to 15 mg as needed. In both cases the operating rule is the same — hold at least four weeks, and only step up if the current dose is well tolerated — and the maximum is a ceiling, not a target.

These are label templates. Real dosing is individualized, and every increase, pause, or step-down is a decision to make with the prescriber who knows your situation. If you want to see exactly where each step lands on your calendar, map your titration schedule with our GLP-1 Titration Schedule calculator, and for the bigger picture on starting and staying on these drugs, see our complete GLP-1 guide.